AbCellera Biologics Azioni (NASDAQ: ABCL)

Ultime notizie per AbCellera Biologics (NASDAQ:ABCL) Azioni

AbCellera Biologics

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Inc

The units are expected to be listed on The Nasdaq Stock Market LLC ("Nasdaq") and begin trading tomorrow, November 1, 2024, under the ticker symbol "BACQU." Each unit consists of one Class A ordinary share and one right to receive one-tenth (1/10) of one Class A ordinary share upon the consummation of the Company's initial business combination.

News

IPOs

BACQU

Reported Earlier, Bleichroeder Acquisition Corp. I Prices $250M Initial Public Offering 25M Units

The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, as defined in the voting question as having estimated glomerular filtration rate (eGFR) &gt;45 to &lt;60 mL/min.1.73 m2 or eGFR &gt;60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) &gt; 30mg/g. As part of the discussion, certain committee members expressed support for sotagliflozin in alternative sub-populations of people with T1D and CKD, where they believed the benefits potentially outweigh the risks.
"We are disappointed in the outcome of today's Advisory Committee vote. However, we were encouraged by the rich discussion and outpouring of support across the diabetes community in favor of sotagliflozin being made available to appropriate people with T1D and CKD," said Dr. Mike Exton, chief executive officer and director of Lexicon Pharmaceuticals. "It's clear from today's discussion that an FDA-approved treatment and clear education on managing risk is urgently needed, and we believe our data supports this need. We look forward to working with the FDA as it completes its review of our NDA, and if approved, making Zynquista available to patients who could benefit from this therapy."

LXRX

Reported Earlier, Lexicon Awaits FDA Decision After Advisory Committee Raises Concerns On Zynquista For Type 1 Diabetes With Kidney Complications

NGVC

Reported Earlier, Natural Grocers by Vitamin Cottage Names Richard Hallé As Chief Financial Officer, Effective January 1, 2025

Reported Earlier, Brookfield Realigns Corporate Structure, Unlocking Value In Asset Management With Broader Shareholder And Index Reach

Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) reported quarterly sales of $1.888 billion which beat the analyst consensus estimate of $1.793 billion by 5.32 percent. This is a 4.95 percent increase over sales of $1.799 billion the same period last year.

Earnings

LVRO

Lavoro FY Sales $1.888B Beat $1.793B Estimate; Net Loss $154.6M Up From $43.7M YoY

The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and the injection process is expected on average to take about 15 seconds. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly intravenous (IV) initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils&#x2A; which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain.

BIIB

Reported Earlier, Eisai And Submit LEQEMBI BLA For Subcutaneous Alzheimer's Treatment To FDA, Targeting Early Disease Stages

Striking employees at Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) are poised to vote on a new contract proposal on Monday. The proposal, which includes a 38% wage increase over four years and a larger signing bonus, has received backing from the workers&#8217; union. 
What Happened: The International Association of Machinists and Aerospace Workers (IAM) stated that they have negotiated the best possible terms with Boeing. Previously, union members had turned down two offers from the company.
Reuters reported on Friday that this new offer comes as Boeing attempts to stabilize its finances amid a seven-week strike involving over 33,000 factory workers on the U.S. West Coast. The strike has significantly affected Boeing&#8217;s cash flow and halted production of key aircraft models.
Acting U.S. Secretary of Labor Julie Su facilitated recent negotiations, lauding both parties for their efforts. President Joe Biden also praised the union and Boeing for reaching a new contract proposal, highlighting the sacrifices made by Boeing&#8217;s machinists.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41642374/cathie-wood-shuffles-her-tech-deck-continues-dumping-tesla-and-palantir-stocks-up-on-amd-and-met?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Shuffles Her Tech Deck: Continues Dumping Tesla And Palantir, Stocks Up On AMD And Meta</a>
Boeing&#8217;s latest offer includes a $12,000 ratification bonus, integrating previous bonuses into workers&#8217; 401(k) retirement accounts. Despite the improved terms, approval remains uncertain as some workers express dissatisfaction due to the absence of a defined-benefit pension.
Why It Matters: The ongoing strike has already cost Boeing an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41524809/boeing-strike-drags-on-union-contract-rejection-adds-further-uncertainty-costs-reco">estimated $2 billion</a> over the last five weeks. The machinists&#8217; rejection of previous offers has added further uncertainty to Boeing&#8217;s financial recovery efforts.
In a bid to bolster its finances, Boeing recently expanded its stock offering, aiming for a <a href="https://www.benzinga.com/markets/equities/24/10/41606547/boeing-eyes-20-7-billion-windfall-as-stock-offering-expands-details">$20.7 billion windfall</a>. The company priced its public offerings at 112.5 million shares of common stock at $143.00 each. 
Price Action: Boeing saw its stock climb higher by 2.77% during the after-hours market after it closed at $149.31 on Thursday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41615718/cathie-woods-sky-high-vision-dumps-shares-of-cybercab-touting-tesla-for-this-evtol-play?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Sky-High Vision: Dumps Shares Of Cybercab Touting Tesla For This eVTOL Play</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Equities

Markets

General

Boeing Sweetens Deal With 38% Wage Hike, $12K Bonus And More To End 7-Week Strike: Vote Set For Monday

SOBR

Reported Earlier, SOBRsafe Regains Nasdaq Compliance In Minimum Bid Price Requirement

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the &#8220;Fear&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Nasdaq Composite falling more than 500 points during the session. The S&amp;P 500 and Nasdaq both recorded their biggest single-day declines since Sept. 3.
Shares of Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) fell around 4% on Thursday after the company reported third-quarter financial results. Shares of Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) fell around 6% on Thursday after the company reported first-quarter financial results.
On the economic data front, U.S. initial jobless claims declined by 12,000 from the previous week to 216,000 in the week ending Oct. 26. The personal consumption expenditure price index rose 0.2% month-over-month in September following a 0.1% increase in August.
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, consumer discretionary, and real estate stocks recording the biggest losses on Thursday. However, utilities and energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 378 points to 41,763.46 on Thursday. The S&amp;P 500 fell 1.86% to 5,705.45, while the Nasdaq Composite fell 2.76% at 18,095.15 during Thursday's session.
Investors are awaiting earnings results from Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), and Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 43.5, the index moved to the &#8220;Fear&#8221; zone on Thursday, versus a prior reading of 54.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Trading Ideas

MSFT

S&P 500 Records Worst Session In Over A Month, Meta And Microsoft Tumble: Greed Index Moves To 'Fear' Zone

Macro Economic Events

Econ #s

Economics

U.K. Nationwide HPI (MoM) For October 0.1% Vs. 0.3% Est.; 0.6% (Revised) Prior

U.K. Nationwide HPI (YoY) For October 2.4% Vs. 2.8% Est.; 3.2% Prior

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) to report quarterly earnings at $2.43 per share on revenue of $48.99 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Chevron shares fell 0.5% to $148.04 in after-hours trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported better-than-expected earnings and sales results for the fourth quarter. The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share. Apple shares fell 1.8% to $221.74 in the after-hours trading session.</li>
<li>Analysts are expecting Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) to post quarterly earnings at $1.88 per share on revenue of $93.94 billion. The company will release earnings before the markets open. Exxon Mobil shares fell 0.04% to $116.73 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) posted stronger-than-expected results for the third quarter on Thursday. Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year. Amazon shares jumped 6% to $197.50 in the after-hours trading session.</li>
<li>Analysts expect Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) to report quarterly earnings at $1.62 per share on revenue of $50.9 billion before the opening bell. Cardinal Health shares gained 0.1% to $108.65 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

AAPL

AMZN

Apple, Amazon And 3 Stocks To Watch Heading Into Friday

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) cost of making the entire Cybercab will roughly equal Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Waymo&#8216;s cost for installing lidar sensors on its robotaxis, according to Ark Invest analyst Brett Winton.
What Happened: The cost of manufacturing the Tesla Cybercab should be half the cost of manufacturing the company&#8217;s Model 3 or Model Y given the Cybercab has half the content as the other vehicles, Winton said. So once production reaches scale, the cost of manufacturing a Cybercab should be nearly $18,000, according to the analyst.
The cost of purchasing Waymo&#8217;s lidar sensors together with installation charges will cost roughly the same amount, Winton said. While the cost of the lidars alone would come at $13,500, installation and wiring will cost another $1,500, taking the total cost of the lidar sensors alone to $15,000.
Waymo installs its sensor suite on electric vehicles made by auto manufacturers such as Zeekr, implying a separate cost for purchasing the vehicle.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">tophat lidar at $7.5k, on-body lidars at $2k &#x2A; 3. Call it $1.5k to install the parts and wiring: $15k cybercab at ~half the content of the average model 3/y should be ~half as expensive to manufacture, scaled. Suggests $18k.
&mdash; Brett Winton (@wintonARK) <a href="https://twitter.com/wintonARK/status/1852047930582274310?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Winton is not alone in expecting the cost of making the Cybercab to be lower than Waymo&#8217;s cost for deploying its robotaxis. 
"ARK estimates that Waymo&#8217;s vehicles cost more than $100,000 to produce, its sensor set alone ~$40,000+, though it is working to reduce costs. Tesla&#8217;s Model 3 costs $40,000, sensors included. While it needs to build backend support for remote vehicle assistance and customer support, Tesla should be able to leverage its existing factory, charging, and service infrastructure to scale efficiently," Ark Invest&#8217;s Tasha Keeney also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41247281/teslas-robotaxi-platform-could-account-for-90-of-ev-giants-enterprise-value-over-th">said in a blog post</a> last month.
Why It Matters: Tesla unveiled its Cybercab with no pedals or steering wheel last month. The vehicle, CEO Elon Musk then said, will enter production &#8220;before 2027&#8221; and be priced below $30,000.
During Tesla&#8217;s third-quarter earnings call last month, Musk said that the company expects to start a ride-hail service in Texas and California starting next year, <a href="https://www.benzinga.com/news/24/10/41484511/palo-alto-may-open-streets-to-tesla-robotaxis-but-california-regulators-will-decide-fate" target="_blank" rel="noreferrer noopener">subject to regulatory approval</a>, with self-driving Model 3 and Model Y vehicles.
However, the vehicles might not all operate as driverless robotaxis initially but with a driver as some states demand it until the company touches certain milestones in terms of miles and hours driven, the company then said.
However, Musk also expressed confidence about the&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne" target="_blank" rel="noreferrer noopener">company operating driverless paid rides sometime next year</a>, placing it as a firm competitor to Alphabet Inc&#8217;s Waymo. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41617327/lucid-to-start-taking-orders-for-gravity-suv-next-week-but-only-for-premium-variant-priced-at-about" target="_blank" rel="noreferrer noopener">Lucid To Start Taking Orders for Gravity SUV Next Week, But Only For Premium Variant Priced At About $95,000</a></li>
</ul>
Photos courtesy: Tesla and Shutterstock

Tech

GOOG

GOOGL

TSLA

Tesla Can Make Cybercab For The Same Money It Takes Waymo To Install Lidar Sensors On Its Robotaxi, Says Ark Analyst

On Thursday, influential economist&nbsp;Peter Schiff&nbsp;took a swipe at&nbsp;MicroStrategy Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) CEO Michael Saylor&#8217;s&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">$42 billion</a> Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investment strategy, likening it to a market trap.
What Happened: Schiff took to X, formerly Twitter, and compared Saylor to &#8220;the Egg Man&#8221; in a metaphorical critique of his Bitcoin investment plans.
Schiff used an egg futures analogy to express his concerns about Saylor&#8217;s strategy. He suggested that MicroStrategy could end up holding a large amount of Bitcoin with no potential buyers, should the market turn.
&#8220;Sell to whom, you&#8217;re the&nbsp;egg man!&#8221; Schiff concluded, implying that Saylor&#8217;s aggressive Bitcoin buying could potentially trap the company in a volatile market.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41606588/if-you-invested-1-000-in-dogecoin-on-jan-1-2021-heres-how-much-youd-have-today?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If You Invested $1,000 In Dogecoin On Jan. 1, 2021, Here&#8217;s How Much You&#8217;d Have Today</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Michael Saylor is the Egg Man. His latest announcement is that <a href="https://twitter.com/search?q=%24MSTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MSTR</a> will spend another $42 billion to buy <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>, funded by issuing $21 billion in debt and $21 billion in equity over the next three years. This reminds me of a joke I heard a long time ago. A client calls his…
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1852004824973185363?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Saylor&#8217;s Bitcoin strategy has been a hot topic in the financial world. Last month, he announced that MicroStrategy plans to invest an additional $42 billion in Bitcoin over the next three years,&nbsp;funded by issuing $21 billion&nbsp;in debt and $21 billion&nbsp;in equity.
Other companies like&nbsp;Coinbase Global Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) have also shown interest in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41645548/coinbase-on-following-microstrategys-bitcoin-playbook-looking-for-opportunities-says-cfo-b">expanding their cryptocurrency investment</a> portfolios.
Coinbase CFO Alesia Haas on Thursday said that the company holds a cryptocurrency investment portfolio on its balance sheet, valued at approximately $1.3 billion at the close of the third quarter.
This portfolio represented close to 25% of Coinbase&#8217;s total cash reserves.
Meanwhile, Bitcoin ETFs are edging closer to becoming the <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41629253/satoshi-nakamoto-could-soon-be-surpassed-by-blackrock-grayscale-as-top-bitcoin-holder">largest collective holder of Bitcoin</a>, potentially surpassing Satoshi Nakamoto&#8217;s legendary holdings.
Price Action: On Thursday, MicroStrategy shares ended the day 1.1% lower at $244.50 and gained 0.7% in the after-hours trading. Bitcoin was seen trading 4.1% lower at $69,321.65, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41609877/bitcoin-flirts-with-all-time-high-ethereum-dogecoin-surge-stay-tuned-says-trader-who-sees-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Flirts With All-Time High, Ethereum, Dogecoin Surge: &#8216;Stay Tuned,&#8217; Says Trader Who Sees &#8216;Only One Untagged High Left&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

MSTR

Michael Saylor The 'Egg Man'? Peter Schiff Points Out A Potential Pitfall Of MicroStategy's $42B Debt-Funded Bitcoin Bet

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens
&nbsp;A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar to the combination of masofaniten and enzalutamide and therefore, unlikely to achieve the primary endpoint of the study&nbsp;
Additional clinical studies with masofaniten including the combination study with abiraterone acetate and apalutamide as well as the remaining investigator sponsored trials will also be terminated and the IND and CTAs in different geographies will be withdrawn
Company will initiate a process to explore and review strategic options focused on maximizing shareholder value

EPIX

Reported Earlier, ESSA Pharma Terminates Phase 2 Study Evaluating Masofaniten Combined With Enzalutamide In Patients With mCRPC

ZEEKR delivered 25,049 vehicles in October 2024, a 92% year-over-year increase. Year-to-date, ZEEKR has delivered 167,922 vehicles in 2024, representing 82% growth over the same period last year. As of the end of October 2024, ZEEKR's cumulative deliveries reached 364,555.

Reported Earlier, ZEEKR Delivered 25,049 Vehicles In October, Up By 92% YoY

Financial and Operational Summary for the Fiscal Year Ended June 30, 2024
<ul>
<li>Revenues increased by approximately RMB 41.6 million (US$5.7 million), or 29% to approximately RMB 183.7 million (US$25.3 million) for the fiscal year ended June 30, 2024 from approximately RMB 142.1 million for the fiscal year ended June 30, 2023.</li>
<li>Gross profit increased by approximately RMB 16.1 million (US$2.2 million), or 28% to approximately RMB 74.8 million (US$10.3 million) for the fiscal year ended June 30, 2024 from approximately RMB 58.6 million for the fiscal year ended June 30, 2023.</li>
<li>Income from operations in the fiscal year ended June 30, 2024 of approximately RMB 10.1 million ($1.4 million), compared to a loss from operations of approximately RMB 44.5 million in the same period of 2023.</li>
<li>The Company increased selling expenses by approximately 40%, and research &amp; development (R&amp;D) by approximately 56% compared to the same period in 2023. Management expects this investment to drive returns in the form of increased revenue in the coming quarters.</li>
<li>Development of B Channels showed strong growth. As of June 30, 2024, Zhibao grew the number of B channels the Company works with from approximately 1,550 to nearly 1,800. B channels are distributed amongst diverse market segments and is a key component to growing our 2B2C embedded digital insurance model.</li>
<li>As of June 30, 2024, the Company reached and served in excess of 15 million end customer users, which management expects will continue to drive revenue in the coming years.</li>
</ul>

ZBAO

Zhibao Technology FY24 Revenue $25.27M Up 29% YoY, EPS $0.06

Reported Earlier, Fujitsu And AMD Join Forces For Sustainable AI Computing, To Accelerate Open-Source Innovations

FUJHY

Subaru H1 Revenue ¥2,266.2B Up From ¥2,213.5B YoY, EPS ¥219.08 Up From ¥198.58 YoY

Reported Earlier, China Caixin Manufacturing Purchasing Managers Index For October 50.3 Vs. 49.7 Est.; 49.3 Prior

In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on AbCellera Biologics (ABCL – Research Report). The company's sh...

KeyBanc Keeps Their Buy Rating on AbCellera Biologics (ABCL)

AbCellera: A Waiting Game With High Uncertainty

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.

Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day. 

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th

Tracking Baker Brothers Portfolio - Q2 2024 Update

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

AbCellera: A Platform To Pipeline Transition

ABBV

ABCL

ABSI

ACAD

AKRO

ARGNF

ARGX

BCRX

BCYC

BEIGF

BGNE

BSGM

EWTX

EXAI

IMCR

INCY

INSM

KYMR

MDGL

NVDA

RARE

REPL

RLAY

ROIV

RVMD

RVMDW

RXRX

RYTM

SDGR

Press Releases

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Reports Q1 2024 Business Results

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera Reports Q2 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Present at Upcoming Investor Conferences in November 2024

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

BioLife Solns

Bruker

ChromaDex

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

AbCellera Biologics

Notizie

Ultime notizie per AbCellera Biologics (NASDAQ:ABCL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO